Invion Limited announced the appointment of Rob Merriel as a Non-Executive Director with effect from 31 August 2020. Mr. Merriel will stand for election at the 2020 Annual General Meeting to be held on 14 October 2020. Mr. Merriel brings deep healthcare sector experience and strong commercial expertise to the Board of Invion. He is a Certified Practicing Accountant (CPA) with over 35 years of experience working in medical research (Hudson Institute of Medical Research and Baker Institute), large public healthcare services (Melbourne Health and Southern Health) and commercial organizations (Pacific Dunlop and Deloitte Consulting). He is currently on the Boards of two biotechnology start-up companies, he has been a Director of two Venture Capital Funds and a Director and Company Secretary of several biotechnology focused medical research institute spin-off companies. Mr. Merriel was appointed as the Chief Financial Officer, Chief Commercialisation Officer and Company Secretary of the Hudson Institute of Medical Research in May 2014, positions he continues to hold. Melanie Farris has been a Director of Invion Ltd. since December 2019. As announced to the ASX on 29 July 2020, Ms. Farris retires as a director effective 31 August 2020 as part of a planned transition.